Will. Good and thanks morning, for joining us. everyone, you, Thank
marked interim and year first The ONCXXX. a study dose our in readout enrollment quarter we less III imipridone countries for Phase by across third III including ACTION complete escalation execution enrollment continued nearing are worldwide, was The second-generation our studies is study of pipeline, active I is Phase in our away. Phase global XX and our continued ACTION Dordaviprone, than of data our potentially
even study's the the with XXX conduct. milligrams the second so change study in safety Committee, one week once prespecified twice administered recommended the administering of continue as review but and always received study treatment the more we essentially days II quarter, independent Phase During ACTION per of this past the or a week II from we arms, to have is news, which treatment a interim undertaken Monitoring on at the schedule. consecutive welcome study, two Data This XXX-milligram is no by arm ACTION where dose case Phase dose per double confirmation
Passing and in It review population also for safety change in participated arm to makes patient as of an evident the meaningful community it Dordaviprone candidate European milestone Meeting who any Association the a of is conduct need unmet the backbone safety support underscores recognize from many that month, study so European Annual this Neuro-Oncology to the program was Glasgow, strengthen to this and we ideal with this Scotland. potential profile with profile a promising very Last time. enthusiasm in degree therapy. both across for the continues no but high monotherapy, IDMC the well-documented only a potential investigators that as a
to Dordaviprone, important presence. a month, Turning SNO also closer so week, will a Society partnership release planning the programs. and will presentations stay SNO, large little the we're also this for have success later we where but for our please as Not engagement conference more home, tuned for will occur next Neuro-Oncology, for organizers of known Abstracts at Houston, to Texas Annual in We the ONCXXX. this pivotal conference that showcase details. our the for we'll with Meeting only view as
in many our forward you of For investigators person. and we're those to seeing attending, looking
Therapeutic to Administration, in with continue to Australia. for TGA, We file make provisional progress approval Goods the or
next action a be within have year-end. file we NDA Australia submission outcome may the potential provisional the year, our for our for end, we now we we on To Having radar aids company in approval as year. an for and interim a a document capacity when opportunity and the should earlier from last not this Dordaviprone's were arose around agile an market judiciously in we're this to lines commercialization the also time interim for year, While was that year and position positive preparing are survival NDA first overall ready readout.
expanded are Phase hospitals in our potential III physicians a $XXX consequently we With the million. a well-laid a potential ongoing population, rapid now and this have over therapies market with Europe, commercialization, uptake upon who study ACTION forecasting approved specific Dordaviprone. global experience we and and foundation access Recall, our programs opportunity have with patient to U.S. and expect treatment there no
to our ONCXXX. Turning second generation imipridone
an program. gather in unselected Our objective CNS year is lead safety and to indications PK population evaluate and patient data to for the the for
report diligently on to lab working for I the inform escalation nearing been is the happy the the nonclinical dose program. has Phase step and I'm to next studies completion,
to studies. near adult see continue ONCXXX well tolerated of we dose pediatric escalation We and as the as in completion patients
in the As months. review for the we program data, plan incoming to preclinical steps clinical the we announce coming next and
a our to the of like Officer. for recognize to Before moment Scientific a of promotion Chief review I'd Allen call Michelle Josh financials, I as turn recent take over to brief the the
Chimerix integral this and team discovery Josh Please the imipridone Josh the call turn and been the on I'll to from well-deserved advanced review across join to With joining trusted class academic has of for in registration XXXX leader financials. the continually program. our that, lead me company an a of has development Since phase brief a many with in promotion. research over acquisition Oncoceutics, congratulating of and compounds Michelle the colleague of to the
